Dr. Reddy's Announces the Launch of Montelukast Sodium Oral Granules

Before you go, we thought you'd like these...
Before you go close icon

Dr. Reddy's Announces the Launch of Montelukast Sodium Oral Granules

HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy's Laboratories (NYS: RDY) announced today that it has launched Montelukast Sodium Oral Granules, a bioequivalent generic version of Singulair® (montelukast sodium) oral granules in the US market on September, 26, 2012, following the approval by the United States Food & Drug Administration (USFDA) of Dr.Reddy's ANDA for Montelukast Sodium Oral Granules.

The Singulair® Oral Granulesbrand had U.S. sales of approximately $61 million for the most recent twelve months ending July 2012 according to IMS Health*.


Dr. Reddy's Montelukast Sodium Oral Granules in 4 mg are available in unit dosage package of 30.

Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYS: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to: www.drreddys.com

Singulair® is a registered trademarkof Merck Co.

*IMS National Sales Perspectives: Retail and Non-Retail MAT July 2012



Media:
S Rajan, +91-40-49002445
at rajans@drreddys.com
or
Investors and Financial Analysts:
Kedar Upadhye, +91-40-66834297
kedaru@drreddys.com
or
Saunak Savla, +91-40-49002135
saunaks@drreddys.com
or
Milan Kalawadia (USA), +1 908-203-4931
mkalawadia@drreddys.com

KEYWORDS:   United States  Asia Pacific  North America  New York  India

INDUSTRY KEYWORDS:

The article Dr. Reddy's Announces the Launch of Montelukast Sodium Oral Granules originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners